WINNIPEG, Jan. 23 /CNW/ - IMRIS Inc. (TSX: IM) today announced that
Capital Health has purchased its advanced neurosurgical imaging system,
IMRISneuro, for the Stollery Children's Hospital and University of Alberta
The only one of its kind in the world, IMRISneuro incorporates a moveable
high field MRI into the surgical suite providing timely, high resolution
images to the medical team during an operation. These images provide surgeons
with richer information during surgery from which they can make better
decisions for their patients.
"By investing in this leading edge technology, we continue to strive to
meet our goal of providing the best medical treatment and outcomes for our
patients," said Deb Gordon, Vice President and Chief Operating Officer,
University of Alberta Hospital, Stollery Children's Hospital and the
Mazankowski Alberta Heart Institute. "We are grateful for the support of our
foundations, who made this investment in patient care possible."
No other system offers the same degree of safety for both the surgical
team and the patient. IMRISneuro does not require the patient to be
transported for scanning, so the optimum position for neurosurgery is never
compromised. Clinical workflow and surgical access to the patient is not
impacted and the magnet is removed completely from the operating room when
scanning is complete. With IMRISneuro, the surgical team is not required to
work within a magnetic field for the entire surgery.
"We are proud to support the goals of Capital Health and to contribute to
the delivery of such a high level of patient care," said David Graves,
President and CEO of IMRIS. "It's also important to us that Canadians have
access to what we believe is the most advanced surgical imaging system in the
IMRISNeuro, with its wide bore, 1.5 Tesla iMRI unit can transition into
and out of the operating room on demand, providing timely surgical imaging in
addition to high quality diagnostic services when the system is not required
for surgeries. This patented ability also provides a high level of financial
value to the hospital.
IMRIS is a global leader in surgical imaging solutions designed to
improve patient outcomes and help them live longer and more enjoyable lives.
IMRIS' key technology benefits of high resolution MR images, improved patient
safety, enhanced surgical efficiency and increased financial viability for
hospitals contribute to a breakthrough surgical imaging offering. The
Company's lead product, IMRISneuro, has been validated by leading U.S.
neurosurgeons and is increasingly being used by world-class neuroscience
centres. IMRIS core MRI technology has multiple product applications with a
second product suite, IMRIScardio, which is actively under development.
For more information, see www.imris.com
This press release may contain or refer to forward-looking information
based on current expectations. These statements should not be read as
guarantees of future performance or results. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from those implied by
such statements. Although such statements are based on management's reasonable
assumptions, there can be no assurance that actual results will be consistent
with such statements. Forward-looking statements are subject to significant
risks and uncertainties, and other factors that could cause actual results to
differ materially from expected results. These forward-looking statements are
made as of the date hereof and we assume no responsibility to update or revise
them to reflect new events or circumstances.
For further information:
For further information: Susan McLeod, Manager, Marketing
Communications, IMRIS Inc., Tel: (204) 480-7094, Email: firstname.lastname@example.org;
Holly Budd, Stollery Children's Hospital, Tel: (780) 407-1567